News & Updates

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

08 Sep 2020 by

In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

08 Sep 2020

Aspirin may accelerate cancer progression in elderly patients

08 Sep 2020

Use of aspirin in older adults with cancer may do more harm than good, exerting an adverse effect on later stages of cancer evolution, as reported in a study.

Aspirin may accelerate cancer progression in elderly patients

08 Sep 2020

INVICTUS crossover analysis boosts potential of ripretinib for GIST

08 Sep 2020 by

The novel switch-control tyrosine kinase inhibitor ripretinib delivered a clinically meaningful benefit for patients with gastrointestinal stromal tumours (GISTs) following crossover from placebo, and had a safety profile consistent with that observed in the double-blind phase, according to the results of the crossover analysis of the INVICTUS trial presented at ESMO GI 2020.

INVICTUS crossover analysis boosts potential of ripretinib for GIST

08 Sep 2020

$Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia$

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

08 Sep 2020

Inotuzumab ozogamicin (InO) provides a safe and effective treatment option for patients with relapsed/refractory acute lymphoblastic leukaemia (R/R ALL) with a high disease burden, a recent study has found.

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

08 Sep 2020

EV-NID1 as potential target for HCC detection and treatment

08 Sep 2020 by

Nidogen 1-enriched extracellular vesicles (EV-NID1) have demonstrated potential as a noninvasive biomarker for early detection of hepatocellular carcinoma (HCC) and as a target for HCC treatment.

EV-NID1 as potential target for HCC detection and treatment

08 Sep 2020

Study reveals genomic landscape of KRAS G12C mutations in Chinese patients

08 Sep 2020 by

A recent study involving 11,951 tumour samples has revealed the genomic landscape of KRAS G12C mutations in Chinese patients.

Study reveals genomic landscape of KRAS G12C mutations in Chinese patients

08 Sep 2020

Fatigue, physical function, distress tied to social functioning in HSCT-treated cancer survivors

06 Sep 2020

In cancer survivors who received haematopoietic stem cell transplantation (HSCT) while they were young, distress, fatigue, and physical functioning are strong correlates of social function, a new study has found.

Fatigue, physical function, distress tied to social functioning in HSCT-treated cancer survivors

06 Sep 2020

Atezolizumab-bevacizumab improves OS in older HCC patients

05 Sep 2020 by

Older patients (aged ≥65 years) with unresectable hepatocellular carcinoma (HCC) may derive greater survival benefit with an atezolizumab + bevacizumab combination compared with sorafenib, according to results of a subgroup analysis of the IMbrave150 trial presented at ESMO GI 2020.

Atezolizumab-bevacizumab improves OS in older HCC patients

05 Sep 2020

Single-port system on par with multiport robotic assisted radical prostatectomy

05 Sep 2020

A single-port system is feasible in robot-assisted radical prostatectomy, with operative and perioperative outcomes similar to those of a multiport robotic approach, a study has shown.

Single-port system on par with multiport robotic assisted radical prostatectomy

05 Sep 2020

Apathy mediates treatment efficacy against cancer-related fatigue

04 Sep 2020

Patient apathy appears to be an important factor in determining the efficacy of interventions targeting cancer-related fatigue (CRF), reports a new study.

Apathy mediates treatment efficacy against cancer-related fatigue

04 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

Aspirin may accelerate cancer progression in elderly patients

Aspirin may accelerate cancer progression in elderly patients

INVICTUS crossover analysis boosts potential of ripretinib for GIST

INVICTUS crossover analysis boosts potential of ripretinib for GIST

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

EV-NID1 as potential target for HCC detection and treatment

EV-NID1 as potential target for HCC detection and treatment

Study reveals genomic landscape of KRAS G12C mutations in Chinese patients

Study reveals genomic landscape of KRAS G12C mutations in Chinese patients

Fatigue, physical function, distress tied to social functioning in HSCT-treated cancer survivors

Fatigue, physical function, distress tied to social functioning in HSCT-treated cancer survivors

Atezolizumab-bevacizumab improves OS in older HCC patients

Atezolizumab-bevacizumab improves OS in older HCC patients

Single-port system on par with multiport robotic assisted radical prostatectomy

Single-port system on par with multiport robotic assisted radical prostatectomy

Apathy mediates treatment efficacy against cancer-related fatigue

Apathy mediates treatment efficacy against cancer-related fatigue